Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：167

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 50 条

[31] Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
Xie, Ning
Liu, Liping
Tian, Can
Hu, Zheyu
Ouyang, Quchang
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
[32] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
Borrego, M. Ruiz
De la Haba, J.
Morales, S.
Ramos, M.
Velasco, A.
Mendez, M.
Carabantes, F.
Barnadas, A.
Garcia, M.
Moreno, J. A.
EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
[33] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
Ruiz, Manuel
De la Haba, Juan
Morales, Serafin
Ramos, Manuel
Velasco, Amlia
Mendez, Miguel
Carabantes, Francisco
Barnadas, Agusti
Garcia, Maria
Moreno, Jose A.
ANNALS OF ONCOLOGY, 2004, 15 : 35 - 35
[34] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
Delea, T. E.
Amdahl, J.
Chit, A.
Amonkar, M. M.
CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
[35] First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Tripathy, Debu
Kaufman, Peter A.
Brufsky, Adam M.
Mayer, Musa
Yood, Marianne Ulcickas
Yoo, Bongin
Quah, Cheng
Yardley, Denise
Rugo, Hope S.
ONCOLOGIST, 2013, 18 (05): : 501 - 510
[36] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
Perez, E.
Lopez-Vega, J. M.
Petit, T.
Zamagni, C.
Freudensprung, U.
Bastiere-Truchot, L.
Walker, R.
Andersson, M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
[37] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
Paridaens, R., Sr.
Wildiers, H.
Dalenc, F.
Rixe, O.
Cadic, V.
Pinel, M.
Roche, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[38] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
Farhat, Fadi
Kattan, Joseph G.
Ghosn, Marwan
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
[39] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
Cardoso, Fatima
Canon, Jean-Luc
Amadori, Dino
Aldrighetti, Daniela
Machiels, Jean-Pascal
Bouko, Yasmina
Verkh, Lev
Usari, Tiziana
Kern, Kenneth A.
Giorgetti, Carla
Dirix, Luc
BREAST, 2012, 21 (06): : 716 - 723
[40] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
Fadi Farhat
Joseph G. Kattan
Marwan Ghosn
Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077

← 1 2 3 4 5 →